Search company, investor...

Founded Year

1961

Stage

PIPE | IPO

Total Raised

$13.05M

About Oscient Pharmaceuticals

Oscient Pharmaceuticals develops anti-infective therapeutics

Headquarters Location

1000 Winter Street Suite 2200

Waltham, Massachusetts, 02451,

United States

781-398-2300

Loading...

Loading...

Oscient Pharmaceuticals Patents

Oscient Pharmaceuticals has filed 15 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/30/2011

12/9/2014

Molecular biology, Genetics, Virus families, Transcription factors, Biotechnology

Grant

Application Date

12/30/2011

Grant Date

12/9/2014

Title

Related Topics

Molecular biology, Genetics, Virus families, Transcription factors, Biotechnology

Status

Grant

Latest Oscient Pharmaceuticals News

Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Dec 2, 2016

Advertisement Topics   Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 01:53 EST 2 Dec 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation since January 2007. Key Findings Provides intelligence on Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation and its subsidiaries since 2007. Information about key financial and legal advisors for Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation's financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation's growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Oscient Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Oscient Pharmaceuticals founded?

    Oscient Pharmaceuticals was founded in 1961.

  • Where is Oscient Pharmaceuticals's headquarters?

    Oscient Pharmaceuticals's headquarters is located at 1000 Winter Street, Waltham.

  • What is Oscient Pharmaceuticals's latest funding round?

    Oscient Pharmaceuticals's latest funding round is PIPE.

  • How much did Oscient Pharmaceuticals raise?

    Oscient Pharmaceuticals raised a total of $13.05M.

  • Who are the investors of Oscient Pharmaceuticals?

    Investors of Oscient Pharmaceuticals include Domain Associates, Highbridge Capital Management, OrbiMed Advisors, Nite Capital Management, Enable Capital Management and 19 more.

  • Who are Oscient Pharmaceuticals's competitors?

    Competitors of Oscient Pharmaceuticals include Affibody, Elusys Therapeutics, GangaGen, Athersys, Sonexa Therapeutics and 7 more.

Loading...

Compare Oscient Pharmaceuticals to Competitors

E
Emiliem

Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

Pulmotect Logo
Pulmotect

Pulmotect is a bio-pharmaceutical company focused on developing products for severe respiratory diseases. The company's main offering is an inhaled therapeutic designed to stimulate the innate immune system in the lungs, providing protection against a range of viral, bacterial, and fungal pathogens. Pulmotect's products are primarily aimed at populations at risk of respiratory complications, such as individuals with COPD, asthma, and immunocompromised patients. It was founded in 2007 and is based in Houston, Texas.

HealOr Logo
HealOr

HealOr is a healthcare provider specializing in a range of medical services within the healthcare industry. The company offers primary care, hormone therapies including bioidentical and transgender options, medical weight loss, treatments for erectile dysfunction and female sexual health, hair loss solutions, integrative medicine, IV therapy, and support for addiction recovery. HealOr primarily serves individuals seeking personalized healthcare and wellness services. It was founded in 2002 and is based in Israel.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

G
GangaGen

GangaGen is a biotechnology company focused on developing treatments for drug-resistant bacterial infections. The company's main offerings include protein antibacterials and bacteriophages, which serve as alternatives to traditional antibiotics. GangaGen's products are designed to prevent and treat bacterial infections, especially those that are resistant to conventional treatments. It was founded in 2001 and is based in Bengaluru, India.

A
Alice Therapeutics

Alice Therapeutics is a biotechnology company.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.